Studies and projects

The CSC conducts studies in cooperation with various clinics and working groups and provides support for specific aspects of study implementation (see services offered; only German description available). In addition, some projects receive direct BIH funding and are carried out at the CSC. 

BeLOVE

One of the main objectives of our 2026 Strategy is the development of large BIH patient database – a core task of CRU. One of the first cohorts for implementing the strategy is the BeLOVE project, launched in July 2017 in its pilot phase. More information about the project can be found here.

Israel Innovation Authority Cooperation

The signing of the Memorandum of Understanding between Charité Universitaetsmedizin Berlin and the Israel Innovation Authority in September 2019 laid the foundation for a common research program. The overall aim of both parties is to facilitate innovations in the field of medtech and digital medicine. Israeli firms in cooperation with researchers of Charité and BIH can receive a funding up to 50 % of the project costs from the IIA and start a cooperative collaboration to develop, test or validate their innovative health care solutions. 

Further information on the program

Finished: BIH CRU Clinical Research Grants

From 2016 to 2019, three studies were funded by the BIH CRU Clinical Research Grant:

OPTICO-ACS

Acute coronary syndrome (ACS) continues to be one of the primary causes of death among patients in western countries. In such cases, an acute cardiac artery occlusion or stenosis results in poor circulation (ischemia) of the heart muscle. The translational OPTICO-ACS study aims to characterize the pathophysiological processes underlying an ACS, and to determine the significance of these processes to the ACS outcome. This is done by examining a high-resolution intracoronary image using optical coherence tomography (OCT) in conjunction with specific clinical and biochemical markers. In the future, it may also be possible to use these biomarkers in post-ACS patients.

Planned number of patients to be recruited: 414 ACS patients. The recruitment and study is being carried out on all three Charité campuses (CBF, CVK, CCM).

Project management: Dr. David Leistner and Prof. Ulf Landmesser, MD.

GESPIC-Crohn

The GESPIC-Crohn study is intended to determine whether a specific profile of the intestinal microbiome may be associated with the development of the (spondylo)arthritis phenotype in patients with Crohn's disease. Secondary objectives are the identification of similarities and differences in the microbiome profile of patients with Crohn's disease and those with primary axial spondyloarthritis (ankylosing spondylitis, also known as morbus Bechterew) and of microbiome changes during and after anti-inflammatory therapy. If the intestinal microbiome is shown to play a role in Crohn's disease in cases where the (spondylo)arthritis phenotype develops, this would open up new approaches to prevention and treatment of arthritic disease.

Planned number of patients: 100 patients with Crohn's disease, 50 patients with primary axial spondyloarthritis. The recruitment and study are taking place at all Charité campuses with hospital beds.

Project management: Prof. Denis Poddubnyy and Prof. Britta Siegmund

AdvIm-Treg

The AdvIm-Treg study is a (phase I, first-in-human) study of adoptive T-cell therapy with regulatory T-cells in patients after kidney transplantation, with intensive immunomonitoring.

Organ transplants are regarded as standard procedure to improve the survival and quality of life of patients with advanced organ failure. Nevertheless, short and long-term transplant maintenance and long-term survival of patients remain critical parameters. Protection of transplant function is a priority, but the side effects of the required life-long immunosuppression medications (toxicity, diabetes, cardiovascular disease, infections, tumours) are very relevant, as they reduce life expectancy and result in high costs. As a result, strategies need to be developed that minimize the use of these drugs or mitigate their side effects.
A promising new option for minimizing medicinal immune suppression could be provided through the use of regulatory T-cells (NTreg). The AdvIm-Treg study examines whether NTregs are a safe and feasible option in treatment of patients after kidney transplantation.

Planned number of patients to be recruited: Maximum 18. The recruitment and study is taking place at the Virchow Clinic campus.

Project management: Prof. Petra Reinke and Prof. Wolfgang Uckert


Finished: Collaborative & Twinning Research Grants

The CRU conducted the recruitment of patients* for the Collaborative & Twinning Research Grants T-Cell Gene Therapy for Cancer and Muscular Organ Failure in Critically Ill Intensive Care Patients (please use the existing link). The reference/link to the project page is sufficient in my opinion.